Loading…
← CockpitCompetitor Analysis › 300453.SZ Jiang Xi Sanxin Medtec Co Ltd Class AOpen in the cockpit ↗

Jiang Xi Sanxin Medtec Co Ltd Class A300453.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum leader 82
Mkt cap
$741M
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$9.62M
20-day average traded
Fwd P/E
16.1×
forward earnings
ROIC−WACC
+13.6 pp
WACC 5.8%
Hurdle
-14 pp
Req g minus delivered
Next earnings
136 days
22 Mar 2027
Close · CNYCN¥9.61
1D-1.3%
1W+3.3%
1M+6.2%
3M-2.1%
6M-4.7%
YTD+10.2%
1Y+4.9%
ATR %2.4%
52w lowhigh10.8% off high

What Jiang Xi Sanxin Medtec does

Employees: 2,297

Jiang Xi Sanxin Medtec at a glance

Size Jiang Xi Sanxin Medtec (300453.SZ) is a China Health Care company (Medical Specialties) with a market value of $741M, the 2942nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥9.61 on 6 Nov 2026.

Performance Over six months the shares fell 4.7%, against -9.0% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 12.1% over the last twelve months (peer median +14.1%); the operating margin is 18.4% (peer median 9.5%).

Valuation It trades at 16.1× forward earnings against a peer median of 20.0× (6th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 13.6 points above its cost of capital (5.8% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011 May 202611 Aug 20266 Nov 2026300453.SZ 94Peer median 91
Six months, rebased to 100: Jiang Xi Sanxin Medtec against the median of its 20 peers (local-currency closes).

Jiang Xi Sanxin Medtec financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.78BCN¥1.63BCN¥1.49BCN¥1.29BCN¥1.33B
Revenue growth—+9%+15%-3%—
Gross profitCN¥712MCN¥541MCN¥489MCN¥421MCN¥420M
EBITDAn/aCN¥418MCN¥356MCN¥304MCN¥275M
Net incomeCN¥290MCN¥265MCN¥227MCN¥207MCN¥185M
Free cash flowCN¥174MCN¥231MCN¥181MCN¥58.7MCN¥195M
Capital expenditureCN¥253MCN¥242MCN¥218MCN¥287MCN¥211M
Total debtCN¥931MCN¥394MCN¥354MCN¥343MCN¥282M

Quarterly statements and history in the cockpit →

Jiang Xi Sanxin Medtec competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-10%0%+10%QDEL688389301234002876300622CTKB688410MLABINMDSNT491000301367PACBVREX6880851501300326SETL1187002950300453.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Jiang Xi Sanxin Medtec is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×QDEL688389002876300622688410MLABINMDSNT301367VREX68808515013003261187300453.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiang Xi Sanxin Medtec is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%688389301234002876300622688410MLABINMDSNT30136768808515013003261187300453.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jiang Xi Sanxin Medtec is the large dot.

Jiang Xi Sanxin Medtec competitors and peer comparison

How Jiang Xi Sanxin Medtec compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiang Xi Sanxin Medtec against its 20 peers (data as of 6 Nov 2026)
Measure300453.SZPeer medianRank in peer set
1-month return+6.2%-2.0%6th highest of 21
6-month return-4.7%-9.0%9th highest of 21
Distance from 52-week high-10.8%-24.9%3rd highest of 21
Revenue growth (TTM)+12.1%+14.1%10th lowest of 21
Operating margin18.4%9.5%5th highest of 21
Forward P/E16.1×20.0×6th cheapest of 15
Growth the price implies (Req g, 7 yrs)-2.1%8.1%5th least demanding of 14
Growth delivered (Del g)+11.8%+13.3%5th lowest of 14
Hurdle (Req g minus delivered)-13.9 pp-9.2 pp7th least demanding of 14
ROIC minus cost of capital+13.6 pp+0.9 pp6th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jiang Xi Sanxin Medtec 300453.SZChina$741M-5%+12%18%16.1×-2.1%+11.8%
QuidelOrtho QDELUnited States$734M-1%-5%-2%12.0×n/an/a
Shenzhen Lifotronic Technology 688389.SSChina$749M-11%+14%13%32.4×13.5%+13.3%
Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZChina$750M+177%-14%3%n/a33.5%-0.6%
Shenzhen Sunnypol Optoelectornics 002876.SZChina$728M-8%+29%5%41.8×11.1%+14.2%
Doctorglasses Chain 300622.SZChina$757M-10%+6%14%24.5×-2.4%+15.7%
Cytek Biosciences CTKBUnited States$758M+26%+5%-22%n/an/an/a
SWS Hemodialysis Care 688410.SSChina$723M-12%+31%19%24.1×16.7%+25.9%
Mesa Laboratories MLABUnited States$718M+23%+3%9%12.6×21.1%+13.2%
InMode INMDUnited States$767M-5%-7%18%10.1×-10.5%+12.4%
Synektik SNT.WAPoland$713M+16%+50%24%11.8×0.1%+40.3%
Livsmed 491000.KSSouth Korea$706M-47%+89%-59%n/an/an/a
BMC Medical 301367.SZChina$780M-13%+37%17%19.8×0.1%+15.6%
Pacific Biosciences of California PACBUnited States$701M+60%+2%-102%n/an/an/a
Varex Imaging VREXUnited States$783M-10%+5%8%20.3×n/an/a
Shanghai Sanyou Medical 688085.SSChina$700M-21%+15%4%50.9×29.1%+6.8%
Shanghai INT Medical Instruments 1501.HKHong Kong$784M-25%+35%21%17.8×-2.1%+23.5%
Shanghai Kinetic Medical 300326.SZChina$698M-7%-28%17%27.4×8.1%-1.9%
Standard Engineering Technology SETL.NSIndia$796M+164%+26%13%n/an/an/a
Cofoe Medical Technology 1187.HKHong Kong$798M-27%+40%10%12.5×-8.0%+6.6%
Allmed Medical Products 002950.SZChina$798M-39%+14%8%n/an/an/a

Questions

Which companies are Jiang Xi Sanxin Medtec's closest peers?
The cockpit's peer set: QuidelOrtho (QDEL), Shenzhen Lifotronic Technology (688389.SS), Anhui Hongyu Wuzhou Medical Manufacturer (301234.SZ), Shenzhen Sunnypol Optoelectornics (002876.SZ), Doctorglasses Chain (300622.SZ), Cytek Biosciences (CTKB), SWS Hemodialysis Care (688410.SS), Mesa Laboratories (MLAB).
Is Jiang Xi Sanxin Medtec expensive compared with its peers?
On forward p/e it trades at 16.1× against a peer median of 20.0×, 6th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has Jiang Xi Sanxin Medtec stock performed?
Over six months to 6 Nov 2026 the shares returned -4.7% against -9.0% for the median peer; over one year +4.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.